You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Thorax editorial by Jenkins and Beasley related to tiotropium respimat
  1. Norbert Metzdorf,
  2. Christoph Hallmann,
  3. Bernd Disse
  1. Department of Clinical Development & Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
  1. Correspondence to Dr Norbert Metzdorf, Department of Clinical Development & Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Binger Strasse 173, Ingelheim 55216, Germany; norbert.metzdorf{at}boehringer-ingelheim.com

https://doi.org/10.1136/thoraxjnl-2013-203228

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Drs Jenkins and Beasley for their comments in the recent editorial regarding tiotropium (SPIRIVA).1 Preceding the Singh et al 2 analysis cited by the authors, Boehringer Ingelheim (BI) had analysed both the tiotropium HandiHaler and Respimat pooled datasets using patient-level data on-treatment as well as including vital status. The results showed a nominally statistically significant reduction for tiotropium HandiHaler and a numerical increase with tiotropium Respimat compared with the respective placebo group for all-cause mortality.

    These results are adequately reflected in the local SPIRIVA product information (http://www.medicines.org.uk/EMC/searchresults.aspx?term=spiriva&searchtype=QuickSearch) …

    View Full Text

    Footnotes

    • Contributors All authors conceived, drafted, read and approved the letter.

    • Funding Boehringer Ingelheim Pharma GmbH & Co KG.

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles